Sadra Medical Raises $19 Million in Series B Financing

Sadra Medical, a privately-held, development stage Silicon Valley firm dedicated to developing innovative new therapies for aortic valve disease, has recently completed a $19 Million Series B round of funding. Oakwood Medical Investors and Boston Scientific joined the company’s Series A investors, Pequot Ventures, Onset Ventures and SV Life Sciences Advisors (SVLS), in the financing.

“We are pleased to be backed by the deep experience base of our investors. Their support will help us in attaining our goal of delivering the best device possible to make percutaneous aortic valve replacement a viable therapeutic option for patients in need,” stated Amr Salahieh, President and CEO of Sadra Medical. “Our momentum is building and we look forward to initiating clinical evaluation of the Sadra Lotus™ Valve within the next several months.”

Raul Perez, president of Oakwood Medical, observed, “We believe percutaneous aortic valve replacement will play a significant therapeutic role in the future. This investment in Sadra Medical reflects the consensus of the group of investors that the innovative second-generation repositionable Lotus prosthesis developed by Sadra has great potential.”

Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in the U.S. have aortic stenosis; however, only a small percentage of those are treated with the current standard of care, open-heart valve replacement surgery, using cardiopulmonary bypass. By delivering a highly effective aortic valve replacement that reduces the risks and morbidity associated with surgery, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today.

Amr Salahieh and a small group of leading-edge cardiovascular clinicians founded Sadra Medical in 2003. Board members include Salahieh, Leslie Bottorff of Onset Ventures, Juliet Tammenoms Bakker of Pequot Ventures, David Milne of SVLS, and Fred Khosravi, CEO of Access Closure.